MSB 1.01% $1.00 mesoblast limited

VILI and MSCs, page-2

  1. 1,249 Posts.
    lightbulb Created with Sketch. 1396
    Many thanks for this info re VILI, totally new to me @The Yankee. And for answering my question.

    I share your scepticism about people taking advantage of pre-publication good news -- it would take superhuman ethics for a hospital worker seeing early good results from any treatment not to seek advantage.

    So, to VILI. Very exciting.
    You wrote: "If the NIH sponsored RCT (Randomized Controlled Trial) for Remestemcel-L for ARDS patients can show repair of VILI, then those tens of thousands of VILI patients who have already been discharged from ICUs, can also be given Remestemcel-L to repair their lungs."

    That would add big numbers to Mesoblast's patient base for the use of Remestemcel-L. Those tens of thousands might enjoy much improved longevity, health and lifestyle if Remestemcel-L repairs the damage. Greatly increased market for the cells. Just as we hope for all the other non-Covid causes of ARDS.

    But there's more. If, as would seem logical (but expert opinion required) the time spent on ventilator increased the risk of VILI then how much more powerful becomes the motivation to get these patients on to Rem-L early and thus off the ventilator early and thus less VILI. The story just keeps getting better.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.00
Change
0.010(1.01%)
Mkt cap ! $1.141B
Open High Low Value Volume
$1.01 $1.01 94.3¢ $8.618M 8.821M

Buyers (Bids)

No. Vol. Price($)
3 43508 $1.00
 

Sellers (Offers)

Price($) Vol. No.
$1.01 34138 2
View Market Depth
Last trade - 16.10pm 01/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.